| 1 |
34541874 | A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas. | 2022 Jun |
2 |
| 2 |
35017312 | Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis. | 2022 Mar 1 |
5 |
| 3 |
35170228 | Effect of food on capsule and granule formulations of selumetinib. | 2022 Apr |
1 |
| 4 |
35289492 | Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series. | 2022 Mar 15 |
1 |
| 5 |
35301838 | Efficacy and safety profile of Selumetinib in symptomatic inoperable plexiform neurofibromas: a systematic review and meta-analysis. | 2022 Mar 17 |
3 |
| 6 |
35410754 | A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib. | 2022 Apr |
2 |
| 7 |
35467749 | Selumetinib in Children with Neurofibromatosis Type 1 and Asymptomatic Inoperable Plexiform Neurofibroma At Risk for Developing Tumor-Related Morbidity. | 2022 Apr 25 |
3 |
| 8 |
33354735 | Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib. | 2021 Mar |
1 |
| 9 |
33549085 | Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change. | 2021 Feb 6 |
1 |
| 10 |
33683166 | Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma. | 2021 May |
2 |
| 11 |
33712511 | FDA Approval Summary: Selumetinib for Plexiform Neurofibroma. | 2021 Aug 1 |
2 |
| 12 |
33721151 | Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. | 2021 Mar 15 |
1 |
| 13 |
33903938 | Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. | 2021 Aug |
5 |
| 14 |
33978635 | Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo. | 2021 Jan-Dec |
8 |
| 15 |
34196005 | Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens. | 2021 Nov |
2 |
| 16 |
34388689 | Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. | 2021 Aug |
1 |
| 17 |
34604034 | Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. | 2021 |
1 |
| 18 |
31913576 | Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies. | 2020 Apr |
1 |
| 19 |
32108293 | Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. | 2020 Apr |
3 |
| 20 |
32187457 | Selumetinib in Children with Inoperable Plexiform Neurofibromas. | 2020 Apr 9 |
1 |
| 21 |
32272491 | The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. | 2020 Jul |
1 |
| 22 |
32504375 | Selumetinib: First Approval. | 2020 Jun |
3 |
| 23 |
32601387 | A molecular basis for neurofibroma-associated skeletal manifestations in NF1. | 2020 Nov |
1 |
| 24 |
32644232 | Treatment of MEK inhibitor-induced paronychia with doxycycline. | 2020 Sep |
1 |
| 25 |
32880495 | Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation. | 2020 Nov |
1 |
| 26 |
32939452 | The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. | 2020 Jan-Dec |
2 |
| 27 |
31151904 | Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. | 2019 Jul |
3 |
| 28 |
28094260 | Targeted therapies: Selumetinib MEKing differences in NF1. | 2017 Mar |
1 |
| 29 |
28029918 | Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. | 2016 Dec 29 |
2 |
| 30 |
22573716 | Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. | 2012 Jul 1 |
1 |